Company Filing History:
Years Active: 1994-1995
Title: Innovations by Robert E. Hruska: Pioneering Work in Doxepin Quantification
Introduction
Robert E. Hruska, an accomplished inventor based in Libertyville, IL, has made significant contributions in the field of pharmaceuticals with three patents to his name. His work primarily focuses on the quantification of doxepins, which are tricyclic antidepressants. Hruska's innovative approaches have paved the way for enhanced immunoassay methods that are crucial in clinical and research settings.
Latest Patents
Hruska's latest patents include innovations in immunoassay methods and reagents for the quantification of total doxepins. His patented methods support the detection of different forms of doxepins, including E-doxepin and Z-doxepin, along with their desmethyldoxepin derivatives. These methods utilize antibodies specifically engineered to bind to total doxepins, enabling accurate quantification in test samples. Another notable patent relates to determining compounds of interest in the presence of interfering substances. This method employs selective chemical modifications to distinguish between similar compounds, facilitating their analytical determination through various techniques such as immunoassay and high-pressure liquid chromatography.
Career Highlights
Robert E. Hruska is associated with Abbott Laboratories Corporation, a leading global healthcare company. His role has allowed him to advance his research and patent innovations, ensuring that his contributions impact the medical field significantly.
Collaborations
Throughout his career, Hruska has collaborated with esteemed colleagues, including Maciej B. Adamczyk and Jeffrey R. Fishpaugh. These collaborations have played a vital role in enhancing the depth and breadth of research conducted in the area of immunoassays and pharmaceutical analysis.
Conclusion
Through his innovative patents and collaborations, Robert E. Hruska continues to make a valuable impact in the pharmaceutical sciences. His contributions not only advance the capabilities of doxepin quantification but also enhance overall diagnostic methodologies, proving essential for patient care and research in mental health.